Podcasts about Lung cancer

In this episode of the Oncology Brothers podcast, we dived deep into the world of antibody drug conjugates (ADCs) in non-small cell lung cancer (NSCLC). We welcomed Dr. Jacob Sands from the Dana-Farber Cancer Institute to discuss the latest ADCs approved for NSCLC, including Trastuzumab deruxtecan (TDXd), Datopotamab deruxtecan (Dato-DXd), and Telisotuzumab Vedotin (Teliso-V). We explored the side effect profiles of these therapies, focusing on critical toxicities such as interstitial lung disease (ILD), mucositis, and peripheral neuropathy. Dr. Sands shared valuable clinical pearls on managing these adverse events, emphasized the importance of proactive monitoring and patient education. Key topics covered in this episode: • Overview of ADCs and their role in NSCLC treatment • TDXd: alopecia, ILD, fatigue, nausea/vomiting • Dato-DXd:  cytopenias, mucositis, dry eyes • Teliso-V: peripheral neuropathy, fatigue, peripheral edema • The evolving landscape of ADCs and future directions in lung cancer treatment Whether you're a healthcare professional or someone interested in oncology, this episode provides essential insights into the management of side effects associated with these innovative therapies. Tune in for practical advice and expert opinions that can enhance patient care in the community setting. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes on practice-changing discussions in oncology! #ADC #NSCLC #TDXd #DatoDXD #TelisoV #ToxicityManagement #OncologyBrothers

Featuring perspectives from Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields, moderated by Dr Stephen "Fred" Divers, including the following topics:  Introduction (0:00) Targeted Therapy for Non-Small Cell Lung Cancer (NSCLC) — Dr Gainor, MD (5:32) Case: A woman in her mid 60s with ALK-mutant metastatic adenocarcinoma of the lung (PD-L1 TPS 70%) — Zanetta S Lamar, MD (17:59) Case: A woman in her mid 80s with EGFR exon 19-deleted adenocarcinoma of the lung with recurrence after 4 years of osimertinib — Jennifer Yannucci, MD (27:53) Case: A woman in her late 60s with HER2-mutant metastatic adenocarcinoma of the lung — Brian P Mulherin, MD (39:41) Case: A man in his early 70s with locally recurrent squamous cell carcinoma of the lung and a MET exon 14 skipping mutation — Sean Warsch, MD (46:39) Case: A woman in her early 70s with ROS1-mutant metastatic adenocarcinoma of the lung that responds to entrectinib and then to pembrolizumab/carboplatin/pemetrexed administered upon disease progression — Dr Yannucci (52:44) Nontargeted Therapy for NSCLC; Small Cell Lung Cancer — Dr Langer (58:16) Neoadjuvant, Perioperative and Adjuvant Anti-PD-1/PD-L1 Antibody-Based Approaches for Patients with Localized NSCLC — Dr Shields (1:14:14) Case: A man in his mid 60s with localized adenocarcinoma of the lung who receives neoadjuvant cisplatin/pemetrexed/pembrolizumab and achieves a pathologic complete response — Dr Mulherin (1:23:19) Case: A man in his early 60s with metastatic mixed adenosquamous NSCLC (PD-L1 TPS 50%) — Sunil Babu, MD (1:30:04) Case: A man in his late 50s diagnosed with extensive-stage small cell lung cancer who receives carboplatin/etoposide/durvalumab — Dr Warsch (1:34:07) CE information and select publications

Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields summarize the treatment landscape and review relevant clinical datasets for patients with lung cancer.CME information and select publications here.

In our new series called Perspectives on Lung Cancer, Dr. Paul Wheatley-Price sits down with two guests, both with a depth of experience in ALK+ lung cancer, which represents about 4-8% of all lung cancer cases in Canada. Dr. Cheryl Ho, medical oncologist at BC Cancer, provides her perspective as a physician treating these types of cancers in her daily practice, while Katie Hulan shares her journey as a patient diagnosed with ALK+ lung cancer in 2021, navigating the healthcare system, and her path to launching ALK Positive Canada to advocate for better awareness of this subtype of lung cancer.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. Laurens Ceulemans, thoracic surgeon at the University Hospitals Leuven in Belgium, about lung volume reduction. Chapters 00:00 Intro 02:41 Right to Repair, Robotics Re-Use 04:53 REPEAT Trial 06:30 JANS 1, PCI After CABG Randomized Trial 08:01 JANS 2, No-Touch vs Conventional Saph Veins 11:04 JANS 3, Sir Terence English & Keyvyn Mohagissi 12:09 CTSNet Recruitment Guide 12:54 Video 1, JCOG0802 Bombshell & Webinar 16:33 Video 2, Endoscopic Cardiac Foreign Body Extraction 17:56 Video 3, First Europe Robotic AVR Perceval Valve 18:42 Video 4, Bilateral VATS Sympathectomy 20:10 Laurens Ceulemans Interview 34:15 Upcoming Events 34:48 Closing They highlighted key takeaways from the procedure and addressed the issue of air leaks. They also discussed bilateral lung volume reduction and emphasized the importance of a team approach. Additionally, they focused on why surgeons should be selecting the healthiest patients for this operation rather than the most critically ill, as well as the future of lung volume reduction.    Joel also highlights recent JANS articles on a multicenter, randomized trial on the PCI of native coronary artery vs saphenous vein graft after prior bypass surgery, a meta-analysis of randomized trials on the outcomes of no-touch vs conventionally harvested saphenous veins for coronary artery bypass surgery, and the death of transplant pioneer Sir Terence English at 93.  In addition, Joel explores bombshell 10-year JCOG0802 results showing lobectomy is superior to segmentectomy for lung cancer, endoscopic extraction of a cardiac foreign body, the first robotic aortic valve replacement in Europe using a Perceval valve, and bilateral VATS sympathectomy for ventricular tachycardia electrical storm. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) PCI of Native Coronary Artery vs Saphenous Vein Graft After Prior Bypass Surgery: A Multicenter, Randomized Trial  2.) Outcomes of No-Touch Vs Conventionally Harvested Saphenous Veins for Coronary Artery Bypass Surgery: A Meta-Analysis of Randomized Trials  3.) Transplant Pioneer Sir Terence English Dies at 93  CTSNet Content Mentioned  1.) Bombshell 10-Year JCOG0802 Results Show Lobectomy Is Superior to Segmentectomy for Lung Cancer  2.) Military Heart Trauma: Endoscopic Extraction of a Cardiac Foreign Body  3.) First Robotic Aortic Valve Replacement in Europe Using a Perceval Valve   4.) Bilateral VATS Sympathectomy for Ventricular Tachycardia Electrical Storm  Other Items Mentioned  1.) Restore Robotics   2.) 2025 Endoscopic Cardiac Surgeons Club Video Competition  3.) 2025 CTSNet Recruitment Guide   4.) Career Center   5.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Marcel D'Allende was in outstanding health, an avid hiker in the mountains overlooking her hometown of Cape Town, South Africa.  However, in October 2021, she began to experience shortness of breath and extreme fatigue.  That led to a diagnosis of Stage IV non-small cell adenocarcinoma, or lung cancer.  Determined not to let cancer define her, she underwent a treatment regimen of radiotherapy, then chemotherapy with carboplatin and pemetrexed, and immunotherapy with durvalumab.  In September 2022, a PET scan revealed Marcel was cancer-free.  It took a little while for her to get back up to speed, but has returned to an active lifestyle, and every weekend, you can find her hiking the mountains.   Marcel thought she was in terrific health, but in the fall of 2021, suddenly she found herself out of breath on a recurring basis.  Her difficulty with breathing became so acute that shortly after beginning a weekend hike with friends, she had no choice but to turn around and return to the base of the mountain.  Things worsened when she had frequent coughing spells.   She was seen by her general practitioner, who recommended she see a pulmonologist.  The pulmonologist called for a CT scan, which revealed a tumor on a lung, and a diagnosis of Stage IV lung cancer in January 2022.    Marcel, who during her adult life smoked cigarettes off and on, immediately thought of her father, who passed away from lung cancer in 2000.  She was afraid she would suffer the same fate.  However, her doctor said that her father's fate didn't have to be hers because of major advances in medicines and technologies in the past twenty years.    She was determined to not let her life be defined by cancer, saying at all times, one on a cancer journey must have hope.  At the same time, she says one can be hopeful without being delusional.    Her diagnosis was difficult enough, but she soon felt the sting of the stigma that often accompanies a lung cancer diagnosis.  When informing friends about her diagnosis, many of them told her should not have smoked. Marcel's treatment begins with six weeks of radiotherapy treatment, which she thought wasn't so difficult.   Next was six cycles of chemotherapy, specifically carboplatin and pemetrexed.  The worst side effects she experienced were nausea and fatigue.   Then, Marcel's oncologist introduced her to a newly-approved form of immunotherapy called durvalumab.  It is usually prescribed for a duration of twelve months, but she was taken off the immunotherapy at the nine-month mark because spots were detected on her lung.  The spots cleared in March.   In September, Marcel D'Allende underwent a PET scan that showed she was cancer-free, which she has been to this day.   She had to start slowly, but Marcel's health is back to normal, and she has returned to her weekend home, hiking trails outside Cape Town.   Additional Resources:   Support Group:   Cancer Association of South Africa  https://www.cansa.org.za   Marcel's Written Account of her Cancer Journey:   https://cansa.org.za/breaking-the-silence-around-lung-cancer/    

 Lynette experienced severe symptoms before diagnosis including inability to walk short distances without collapsing, constant coughing that prevented speaking, and extreme fatigue that made basic activities impossible.Medical professionals initially prescribed antibiotics three times before ordering urgent X-rays and MRI scans, which led to immediate referral to a lung cancer specialist and hospitalization.Hospital procedures included draining 1.5 liters of fluid described as "porridge-like" from Lynette's lung cavity, followed by surgery to fuse the pleural lining, but the left lung had completely collapsed making the cancer inoperable.Doctors determined chemotherapy was not an option and sent Lynette home for palliative care with an estimated survival time of 12-18 months.Monica Hayes, Lynette's daughter and a registered nurse, developed a comprehensive treatment protocol inspired by her partner Craig Burrells who had survived cancer using similar methods.Treatment protocol consisted of THC oil administered rectally three times daily at seven-hour intervals, combined with a complete alkaline plant-based diet eliminating sugar, dairy, and meat.Monica initially administered the THC suppositories herself as a nurse before teaching her mother to self-administer, noting the confronting nature of the intimate medical care.Improvements became visible within the first two weeks including elimination of coughing, reduced shortness of breath, increased energy levels, and Lynette's ability to work in her garden.Additional treatments included ivermectin, fenbendazole antiparasitic medications, alkaline water, and CBD oil to counteract the psychoactive effects of THC while maintaining therapeutic benefits.After three months of treatment, scan results showed 80% cancer clearance, prompting Lynette to perform a celebratory tap dance for her oncologist.Lynette's oncologist was thrilled with the results and noted perfect blood work, though the medical team was not informed about the cannabis treatment due to legal concerns in Australia.Family members, initially skeptical, became amazed by the transformation and now call Monica a "miracle worker" after witnessing Lynette's complete symptom reversal.Lynette's next scan is scheduled for Friday to determine if further improvement has occurred, with hopes that her partially collapsed lung may have self-corrected.Both women advocate for cannabis legalization and encourage others facing terminal cancer diagnoses to consider THC oil treatment as a source of hope when conventional medicine offers only palliative care. Visit our website: CannabisHealthRadio.comFind high-quality cannabis and CBD + get free consultations at MyFitLife.net/cannabishealthDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us a textLung cancer is often discovered too late, when treatments are expensive and survival rates are low. But what if routine chest x-rays could flag cancer early…long before symptoms appear? AI is transforming everyday imaging into a powerful early detection tool, reshaping screening economics and saving lives around the world. Prashant Warier, CEO and Founder of Qure.ai, joins CareTalk to discuss how AI enables earlier diagnosis, why chest x-rays are an untapped opportunity for detection, and what it takes to integrate AI into national health systems at scale.

To end season 2, our expert panel discusses some of the challenges and misconceptions that need to be overcome in the fight against lung cancer and the progress being made. Our host Dr Ellie Cannon is joined by Dr Jesme Fox, Medical Director at the Roy Castle Lung Cancer Foundation, and Stefano Podesta, Oncology Commercial Lead at Pfizer UK. PP-UNP-GBR-13858 / December 2025 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with two thoracic oncologists practicing in New Zealand—Dr. Laird Cameron from Auckland Hospital and Dr. Annie Wong from the University of Otago—about the unique challenges and approaches to lung cancer care in their island nation of 5.4 million people. The conversation explores New Zealand's healthcare coverage system, patient population characteristics including smoking rates, the current state of lung cancer screening programs, and how molecular testing is conducted for non-small cell lung cancer patients. Drs. Cameron and Wong discuss access to targeted therapies and immunotherapy, the drug approval process in New Zealand, cultural considerations and health disparities affecting lung cancer treatment, and the clinical research infrastructure available in the country. This global perspective highlights how IASLC members face different regional challenges while working toward common goals in advancing lung cancer care.

Lung cancer remains the leading cause of cancer death in Virginia, and some communities in Hampton Roads — including nearby rural areas — face persistent challenges in diagnosis and access to specialty care.

Dr. Trudy G. Oliver is a Professor in the Department of Pharmacology & Cancer Biology as well as a Duke Science and Technology Scholar at Duke University. Trudy's research focuses on small cell lung cancer, a disease known for its remarkable ability to "shape-shift" or undergo cellular plasticity. This adaptability allows cancer cells to change types and develop different therapeutic vulnerabilities (or invulnerabilities), making treatment especially challenging and preventing the development of a one-size-fits-all approach. When she's not in the lab, Trudy unwinds with walks, jogs, music, and true-crime podcasts. She also enjoys spending quality time with friends, family, and her two energetic orange kittens named Basal and Tuft after her favorite lung cell types. She received her Bachelor's degree in chemistry from Oklahoma Baptist University, and her PhD in cancer biology from Duke University. Afterwards, she conducted postdoctoral research at the University of North Carolina, Chapel Hill, and subsequently at MIT. Trudy served on the faculty at the University of Utah for more than a decade before joining the faculty at Duke University where she is today. She has received numerous awards and honors for her work, including the Heine H. Hansen Lectureship Award for Small Cell Lung Cancer from the IASLC World Lung Conference, the William C. Rippe Award for Distinguished Research in Lung Cancer from the Lung Cancer Research Foundation, the Lung Cancer Discovery Award from the American Lung Association, the American Cancer Society Research Scholar Award, the Damon Runyon-Rachleff Innovation Award, and the Jimmy V Scholar Award from the V Foundation for Cancer Research. In this interview, Trudy shares more about her life and science.

Dr. Tharwat Ghattas, oncologist with Ghattas Oncology by Highland Clinic, shines light on Lung Cancer Awareness Month. Dr. Ghattas discusses the latest in screening, early detection, risk factors, and breakthroughs in treatment. He also shares practical guidance on prevention and how patients and families can navigate a lung cancer diagnosis with confidence and hope.

How do leading oncologists interpret the abundance of molecular tests, genomic data, and biomarkers to create a lung cancer patient's treatment plan? In this episode of the 2025 NSCLC Creator Weekend™ series, our tumor board discusses the complexities of lung cancer treatment, including new systemic therapies, lung cancer staging, and the role of molecular diagnostics and liquid biopsies. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS The panel, featuring specialists from various institutions, discusses the specifics of sequencing therapies, the impact of targeted and immunotherapies, and the nuances of treating different patient profiles, including non-smokers and those with specific genetic mutations. The conversation also touches on the integration of new staging systems, the benefits of multidisciplinary clinics, and the ongoing evolution of cancer treatment trials. The discussion aims to provide clarity on the latest advancements and future directions in managing lung cancer, emphasizing the importance of tailored treatment plans and the potential of emerging technologies. --- TIMESTAMPS 00:00 - Introduction05:16 - Molecular Diagnostics and Liquid Biopsy21:43 - Targeted Therapy Options27:29 - Managing Toxicities and Treatment Strategies33:13 - Challenges with Immunotherapy in Special Cases34:07 - Lung Transplantation in Cancer Patients48:38 - Multidisciplinary Clinics and Collaboration01:06:29 - Future Directions --- RESOURCES ADAURA Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2027071 Gomez NSCLChttps://pmc.ncbi.nlm.nih.gov/articles/PMC5143183/

In this special edition of the Best Science in Lung Cancer series, Leah Backhus, MD, joins host Erin Gillaspie, MD, to explore key takeaways from WCLC, including how precision data, surgical restraint, and breakthrough immunotherapy are transforming care.

In this special edition of the Best Science in Lung Cancer series, host Erin Gillaspie, MD, speaks with Paula Ugalde, MD, to examine findings from ELCC, including restaging in the neoadjuvant era, redefining resectability, the use of AI in multidisciplinary precision care, and the current de-escalation debate.

In this special edition of the Best Science in Lung Cancer series, host Erin Gillaspie, MD, sits down with Brendon Stiles, MD, to discuss insights from ASCO, including perioperative immunotherapy, CheckMate 816, and expanding surgical boundaries.

Lung cancer is the leading cause of cancer-related death worldwide and is classified into two main types: non-small cell lung cancer (NSCLC), which accounts for most cases and the more aggressive small cell lung cancer (SCLC). Early detection is crucial for improving outcomes, but symptoms often emerge late in the disease course. In episode 126, Dr Hannah Rosa looked at the challenges of diagnosis, reviewed guidelines and latest research and discussed when to continue investigations after a normal chest X-ray. In this episode, Dr Roger Henderson gives an overview of detecting lung cancer in primary care and looks at treatment – including newer options for some late-stage cancers.Access episode show notes containing key references and take-home points at: https://gpnotebook.com/en-GB/podcasts/oncology/ep-185-lung-cancer.Did you know? With GPnotebook Pro, you can earn CPD credits by tracking the podcast episodes you listen to. Learn more.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with Prof. Li Zhang and Dr. Elaine Shum about recent progress in antibody–drug conjugates (ADCs) for EGFR-mutant non-small cell lung cancer (NSCLC). They discuss new approvals of datopotamab deruxtecan (in the United States) and sacituzumab tirumotecan (in China), key findings from the TROPION and OptiTROP trials, and emerging agents. The conversation highlights the advances in efficacy, safety, and combination strategies that are shaping the evolving treatment landscape for patients with EGFR-mutant NSCLC. Guest: Li Zhang, MD Professor, Medical Oncology Department Sun Yat-Sen University Cancer Center No Social Guest: Elaine Shum, MD Assistant Professor Director of Cancer Screening Programs New York University Perlmutter Cancer Center

Lung cancer is the most prevalent cancer in the Rochester and Finger Lakes region. That's according to experts at the University of Rochester Medical Center. They say screening has been underutilized due to the stigma of the disease. This hour, we discuss their efforts to change that. They also explain what they call a "soup to nuts" approach to addressing the disease, which includes prevention and screening, early diagnosis, and advanced treatment options. Our guests: Racquel Stephen, health, equity and community reporter and producer for WXXI News Charles Kamen, Ph.D., M.P.H., associate director of community outreach and engagement at Wilmot Cancer Institute at the University of Rochester Medical Center M. Patricia Rivera, M.D., C. Jane Davis & C. Robert Davis Distinguished Professor in Pulmonary Medicine and chief of the Pulmonary and Critical Care Medicine Division at University of Rochester Medical Center Joyce Lucas, patient ---Connections is supported by listeners like you. Head to our donation page to become a WXXI member today, support the show, and help us close the gap created by the rescission of federal funding.---Connections airs every weekday from noon-2 p.m. Join the conversation with questions or comments by phone at 1-844-295-TALK (8255) or 585-263-9994, email, Facebook or Twitter. Connections is also livestreamed on the WXXI News YouTube channel each day. You can watch live or access previous episodes here.---Do you have a story that needs to be shared? Pitch your story to Connections.

Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk about the latest health news. Dr. Marty discusses a lung cancer study that was conducted by Northwestern Medicine and who should be screened.

If you are sick or know someone who is, this podcast will build and strengthen your faith as you believe God for a healing miracle. 13 years ago God dramatically healed me of lung cancer, and He can do the same for you when you believe and stand on His promises! God is not a man that He should lie, nor will He change His mind, what He has said that will He do (Numbers 23:19). You can be certain of this one thing, God answers prayer! Jesus said 'lay your hands on the sick and they shall recover'. If you are in need of healing put your hand where the sickness is and say this prayer in faith and with conviction. - Then do what you could not do! I know Jesus is alive! I believe the Bible: God cannot lie! Your Word says Jesus took my sickness and healed me - so by faith I take my healing. In Jesus' Name I will fight in prayer and in the Word of God until I am healed! I command you devil, get out of my body! My body is a Temple of the Holy Spirit. Devil, get out of my life, my home, my family! In Jesus' Name I defeat you! I will not die, but live, and declare the works of the Lord! And I will live in health and victory until Jesus comes! Amen! Listen to my testimony, and be inspired by the beautiful worship of Vinesong, as together we declare God's healing power over your life. 'God answers prayer' and 'Run to the Father' used by kind permission of Vinesong

Dr. Sumedha Sonde, pulmonologist and critical care physician at Hamilton Physician Group - Specialty Care in Dalton, Georgia. Dr. Sonde completed residency training in Anesthesia and Pain Management and additional residency training in Internal Medicine. She then completed a Pulmonary and Critical Care fellowship in New York.Dr. Sonde treats patients with sleep or pulmonary disorders. chronic obstructive pulmonary disease (also referred to as COPD), asthma, pulmonary fibrosis, lung cancer, COVID conditions, pneumonia, acute and chronic pulmonary hypersensitivity conditions, pulmonary hypertension, bronchiolitis, and more. For more information or an appointment at Hamilton Physician Group - Specialty Care, call 706-529-3072 or visit VitruvianHealth.com/specialtycare. This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

Think vaping is safer than smoking? This Baptist HealthTalk episode will make you think twice.In this new conversation with pulmonologist Dr. Sosa, he breaks down what really happens when you vape and why the risks are much more serious than most people realize.You'll hear: • What's actually inside a vape and why it matters • How vaping affects lungs, especially in developing teens • The hidden chemicals and exposures most people never hear about • The truth behind “one pod equals one pack” • What parents need to know about the products kids can access today • Why flavors make addiction even easier • How fast habits form and why they're so hard to breakIf you or someone you love vapes, this is a conversation you don't want to miss.Host:Johanna GomezAward-Winning Host & JournalistGuest:Andres F. Sosa, M.D.General and Interventional PulmonologistBaptist Health Baptist Hospital

“We have made great progress in treating lung cancer, but we still have a long way to go,” said Triparna Sen, PhD, a James scientist who specializes in translational research to better understand and treat lung cancer. Listen as Sen explains the biology and differences between the two different types of lung cancer (non-small cell and the less common, but more aggressive small cell); the latest treatments, including immunotherapy; and how a better understanding of the biology of cancer cells has led to improved drugs (such as immunotherapy) and better outcomes for patients. She also described how cancer cells are able to adapt and transform their biology and actually become “a new form of cancer.” Once this happens, over the course of several months, the immunotherapy drugs “no longer recognize the tumor.”

RaeAnn Tucker from the Henry and Stark County Health Departments joined Wake Up Tri-Counties to discuss Lung Cancer Awareness Month, the Great Smokeout on November 20th, insurance navigators, Covid and flu vaccines, the A1C test special, the food drive blood test special, and food safety. Residents of Henry and Stark Counties are encouraged to join the Great American Smokeout on November 20th, aiming to take that important first step toward quitting smoking. Local health departments are highlighting the significant health benefits of becoming tobacco-free, especially as November marks both Lung Cancer and Diabetes Awareness Months. Area clinics are offering discounted hemoglobin A1C tests for diabetes monitoring and updated COVID-19 and flu vaccinations. As the holidays approach, officials also urge extra food safety precautions to prevent illness at gatherings. For health support, resources, and vaccination information, contact the local health department or First Choice Healthcare clinics.

Early detection saves lives. Learn how advanced screening programs and robotic technology are transforming the fight against lung cancer. In this episode, Dr. Peter Olivieri, III, a pulmonologist and critical care leader at UM Baltimore Washington Medical Center, explains who should be screened, how the process works, and what makes today's minimally invasive diagnostic tools so precise and effective.

Lung cancer is the third most common cancer in the U.S. It's caused by harmful cells in your lungs growing unchecked. Treatments include surgery, chemotherapy, immunotherapy, radiation and targeted drugs. Screening is recommended if you're at high risk. Advances in treatments have caused a significant decline in lung cancer deaths in recent years. ​ Lung cancer is a disease caused by uncontrolled cell division in your lungs. Your cells divide and make more copies of themselves as a part of their normal function. But sometimes, they get changes (mutations) that cause them to keep making more of themselves when they shouldn't. Damaged cells dividing uncontrollably create masses, or tumors, of tissue that eventually keep your organs from working properly. Lung cancer is the name for cancers that start in your lungs — usually in the airways (bronchi or bronchioles) or small air sacs (alveoli). Cancers that start in other places and move to your lungs are usually named for where they start (your healthcare provider may refer to this as cancer that's metastatic to your lungs). ​ There are many cancers that affect the lungs, but we usually use the term "lung cancer" for two main kinds: non-small cell lung cancer and small cell lung cancer.  Other types of cancer can start in or around your lungs, including lymphomas (cancer in your lymph nodes), sarcomas (cancer in your bones or soft tissue) and pleural mesothelioma (cancer in the lining of your lungs). These are treated differently and usually aren't referred to as lung cancer.  (CREDITS: Cleveland Clinic)

The UK Markey Cancer Center's upcoming Lung Cancer Forum scheduled for Dec. 11. Dr. Weisi Yan joined us to chat about it.  Learn more about Weisi Yan, MD, PhD  

Join Dr. Narjust Florez as she explores complementary and integrative medicine in lung cancer care with leading experts Dr. Ting Bao, Dr. Jun J. Mao, and Dr. Lisa Davis. This episode clarifies the differences between alternative, complementary, and integrative approaches while addressing oncologists' concerns about safety and drug interactions. Learn where to find reliable information, what the research shows about treatments like acupuncture and supplements, and how patients can safely incorporate these therapies into their cancer journey. Guests: Ting Bao, MD, MS, FSIO Co-Director, Leonard P. Zakim Center for Integrative Therapies and Healthy Living Member of the Faculty, Harvard Medical School Dana-Farber Cancer Institute Jun J. Mao, MD, MSCE Chief, Integrative Medicine Service Laurance S. Rockefeller Chair in Integrative Medicine Professor of Medicine, Weill Cornell Medicine Memorial Sloan Kettering Cancer Center Lisa Davis, PharmD, FCCP, BCPS, BCOP, Clinical Professor, Pharmacy Practice & Science The University of Arizona, R. Ken Coit College of Pharmacy

In this episode, Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer, including:TROP2-targeting ADCs: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan TROP2 ADCS for patients with EGFR-mutated NSCLCTIGIT-targeting agents: domvanalimab, rilvegostomigPresenters:Benjamin Levy, MD, FASCOAssociate ProfessorJohns Hopkins School of MedicineClinical DirectorJohns Hopkins Kimmel Cancer Center, National Capitol Region (NCR)Washington, DCAlex Spira, MD, PhD, FASCODirector Clinical ResearchVirginia Cancer SpecialistsCEO NEXT Oncology VirginiaFairfax, VirginiaContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program:https://bit.ly/4qZLR6B Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Only about one in six lung cancer cases nationwide are caught early enough for curative treatment. In Hampton Roads, health advocates say it's time to widen screening guidelines.

Lung cancer is the deadliest cancer in Ireland with an estimated 1900 deaths per annum and its the second most common cancer in Ireland for women. While many associate this type of cancer with smokers, one in five diagnosed people have never smoked in their lives. One of these people is Susan Leatham who was diagnosed in 2021 and Susan spoke to Pat this morning along with Helen Forristal, Director of Nursing with the Marie Keating Foundation.

As lung cancer treatments become more complex, is a collaborative tumor board more essential than ever? We're kicking off the 2025 NSCLC Creator Weekend™ series with an in-studio panel discussion on the multidisciplinary management of lung cancer. The panel includes experts from medical oncology, thoracic surgery, radiation oncology, and interventional pulmonology from major institutions in Los Angeles. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS They discuss the operation of tumor boards at their respective institutions, the impact of virtual meetings, optimal strategies for mediastinal staging, the management of early-stage lung cancer, and the emerging role of ablation therapy. The conversation dives into the complexities of treating patients with recurrence or metastatic disease, highlighting the importance of collaborative decision-making in navigating these challenging scenarios. The episode emphasizes the critical role of multidisciplinary tumor boards in providing informed, patient-centered care. --- TIMESTAMPS 00:00 - Introduction06:59 - Role of Pulmonologists in Tumor Boards12:08 - Importance of Tissue Diagnosis24:52 - Lung Cancer Screening and Stigma34:01 - Interventional Radiology and Biopsies46:21 - Challenges with Immunotherapy and Radiation53:44 - The Importance of Multidisciplinary Teams54:24 - Final Thoughts --- RESOURCES American Lung Association 2024 Datahttps://www.lung.org/getmedia/12020193-7fb3-46b8-8d78-0e5d9cd8f93c/SOLC-2024.pdf National Lung Screening Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1102873 Checkmate 816https://www.nejm.org/doi/full/10.1056/NEJMoa2202170 PACIFIC Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1709937

US Veterans are at a heightened risk for lung cancer due to service-related exposures. Integrating clinical research into routine oncology care at the US Department of Veterans Affairs (VA) can help bring clinical trials closer to where Veterans live and improve access to cutting edge therapies. In this episode, CANCER BUZZ speaks with Millie Das, MD, chief of oncology at the VA Palo Alto Health Care System, about the collaborations and institutional support that allowed them to launch lung cancer clinical trials and the role industry has played.     "My primary motivation was just to allow veterans access to trials in the same way that I saw my patients at Stanford have access to clinical trials." - Millie Das, MD   "One of the biggest myths is that you can't work with pharma within the VA and I think just trying to break down some of these old myths was a challenge." - Millie Das, MD     Guest:                  Millie Das, MD Chief, Oncology VA Palo Alto Health Care System Clinical Professor Stanford University Stanford, CA     Additional Reading/Resources   ·      Veterans Care Resource Library ·      Improving Cancer Care for Native American Veterans: A Model of Interagency Collaboration

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. In this episode, Dr Camidge sat down with Mark Socinski, MD, a medical oncologist and the executive medical director of the AdventHealth Cancer Institute in Orlando, Florida. Drs Camidge and Socinski discussed the highlights of Dr Socinski's career trajectory, as well as the personal influences that helped him arrive where he is today. Socinski describes himself as a clinician and clinical investigator with 35 years of focus on lung cancer. His role as executive director of the AdventHealth Cancer Institute involves maintaining an active clinic 1 day a week and dedicating the rest of his time to administrative duties, including recruitment and building infrastructure at the institution. In the interview, Dr Socinski explained that he was influenced to enter a career in medicine because of role of the family practitioner he knew growing up. He went on to receive undergraduate and medical degrees from the University of Vermont in Burlington. After training at Dana-Farber Cancer Institute in Boston, Massachusetts, he began his career in private general oncology practice in Vermont before seeking a more academic, subspecialty environment. He joined the University of North Carolina to concentrate on lung cancer, where he pioneered dose-escalation trials using conformal radiotherapy. Dr Socinski then described his move to the University of Pittsburgh Medical Center in Pennsylvania. There, he became the chair of the lung pathway, which limits treatment options to a single, expert-agreed standard of care based on efficacy, toxicity, and cost, thus reducing treatment heterogeneity and controlling costs. Thereafter, Dr Socinski moved to AdventHealth, attracted by the institution's goal to achieve National Cancer Institute designation and build a major cancer program. Dr Socinski shared that he finds it gratifying to care for patients and lead the development of the institute.

Breaking down the impact and legacy of Nancy Pelosi following her retirement announcement. A new state law makes it easier for high school students to go to CSUs. Finally, analyzing the annual State of Lung Cancer report through a California lens.

Dr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here.

Click here to view the full article on Oncology Data Advisor: https://oncdata.com/mary-pasquinelli-sybil-ai In this episode of Exploring AI in Oncology, Dr. Waqas Haque speaks with Mary Pasquinelli, DNP, Nurse Practitioner and Director of the Lung Screening Program at the University of Illinois (UI) Health, about the evolving role of screening and artificial intelligence (AI) in lung cancer detection. Their conversation spans program design, health equity, AI validation in diverse populations, multimodal detection with circulating tumor DNA (ctDNA) and imaging, and practical strategies that boost adherence and impact in both academic and community settings.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Elene Mariamidze moderates a discussion in Georgian about highlights from the conference with Dr. Salome Begijanashvili, Dr. Beka Shubitidze, and Dr. Mariam Tchiabrishvili.

Welcome to another episode of the Oncology Brothers podcast! In this episode, we are joined by Dr. Rami Manochakian from the Mayo Clinic to discuss the latest practice-changing studies presented at ESMO 2025, focusing on lung cancer. Episode Highlights: MDT-BRIDGE: Trial for resectable and borderline resectable non-small cell lung cancer (NSCLC) stressing the importance of a multidisciplinary approach. FLAURA2 Update: showcasing the overall survival benefits of osimertinib combined with chemotherapy for EGFR-positive NSCLC. SOHO-01 & Beamion LUNG-1: emerging HER2-positive NSCLC treatments, Zongertinib and Sevabertinib. Discussion on the significance of NGS testing in identifying mutations and tailoring treatment options for patients. Join us as we explore these important studies and their implications for improving patient outcomes in lung cancer care.  Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to subscribe for more updates on practice-changing research and major conference highlights! #ESMO2025 #LungCancer #NSCLC #MDT #Zongertinib #Sevabertinib #Osimertinib #OncologyBrothers

In this podcast, we review a comparison of outcomes in patients 65-74 years old from SEER-Medicare and NLST datasets in stage I lung cancer with study first author, Dr. Nichole Tanner as well as Dr. Neal Navani.

Drs. Cooper and Rotow review the challenges of CNS involvement in HER2+ NSCLC, emphasizing the importance of baseline and ongoing brain imaging, and the emerging understanding of CNS penetrance for HER2-targeted therapies. They explore strategies for managing brain metastases, including balancing local therapies, including radiation with systemic treatments, and highlight the need for multidisciplinary approaches and further research on CNS activity in clinical trials.

Drs. Rotow and Cooper explore the evolving landscape of HER2+ NSCLC treatment, highlighting recent advancements in targeted therapies like HER2 TKIs and antibody-drug conjugates. They emphasize the importance of comprehensive biomarker testing, the significance of personalized treatment approaches, and the exciting progress in providing more effective and tolerable second-line therapies for patients. The discussion underscores the field's movement toward precision medicine and the potential for future combination strategies and improved patient outcomes.

Drs. Cooper and Rotow discuss first-line treatment strategies for HER2+ NSCLC, highlighting the importance of comprehensive molecular testing and emerging targeted therapies. Key considerations include the efficacy of antibody-drug conjugates and TKIs, with ongoing clinical trials evaluating their potential as frontline treatments. The discussion emphasizes the need for personalized treatment approaches based on individual patient characteristics, molecular features, and the evolving landscape of HER2-targeted therapies.

I recently had an ApoB test and am surprised that it isn't lower than it is.  Can you explain?I have an ascending thoracic aortic aneurysm.  How can I keep it from enlarging?Why are you against whole-body scans? Aren't they helpful?Can I take magnesium L-threonate while also taking magnesium glycinate?

Will Truheight vitamins really make your kids grow?Where can I learn more about complementary medicine and nutrition?The balls of my feet are sore along with my toes. Is this a vitamin deficiency?

In this episode, Ziad Hanhan, MD, hosted a discussion about lung cancer diagnosis, surgical management, and evolving treatment paradigms. Dr Hanhan is a thoracic surgeon at Hackensack Meridian Health, chairman of Surgery at Bayshore Medical Center in Holmdel, New Jersey, and chief of Thoracic Surgery at Riverview Medical Center in Red Bank, New Jersey. He was joined by: Thomas Bauer, MD, the chair of surgery at Jersey Shore University Medical Center in Neptune Township, New Jersey, and Hackensack Meridian Health School of Medicine Rachel NeMoyer, MD, a thoracic surgeon at Hackensack Meridian Health Drs Hanhan, Bauer, and NeMoyer discussed current standards and future directions in thoracic oncology, emphasizing multidisciplinary collaboration and technological innovation. The conversation opened with an overview of lung cancer epidemiology, and the experts noted that this disease remains the leading cause of cancer-related mortality in both men and women. They explained that approximately 90% of lung cancer cases are attributable to tobacco use, making cessation a key preventive measure. They also emphasized that early detection through low-dose CT screening improves outcomes when the disease is identified at an early stage. However, despite these advances, they stated that most lung cancer cases in the United States continue to be diagnosed at stage III or IV, underscoring the need for improved screening adherence. They expanded on current lung cancer screening guidelines and noted that lung cancer often presents with nonspecific symptoms, such as chronic cough or hemoptysis, and that many cases are discovered incidentally on imaging. The surgeons also discussed diagnostic strategies for pulmonary nodules and emphasized a patient-tailored approach that balances diagnostic yield with procedural risk. They also acknowledged that emerging modalities, such as liquid biopsy and breath-based DNA detection, are promising but still investigational. They underscored that frailty assessment remains integral to surgical candidacy determination, with both clinical evaluation and pulmonary function testing guiding decision-making. The team also highlighted the role of multidisciplinary tumor boards in integrating surgical, medical, and radiation oncology perspectives. For early-stage disease, surgery remains the standard, whereas patients with stage III disease typically receive neoadjuvant therapy incorporating immuno-oncology agents. The group also discussed expanding surgical indications in select stage IV cases, reflecting improved survival associated with immunotherapy.

A Colorado doctor was diagnosed with the same lung cancer he's researched and treated all his life. He only recently decided to share his story when chemotherapy made him horribly sick. Dr. Ross Camidge talks about sharing the same path as his patients, and how he views death and what comes next. Then, from artwork to hidden history on the walls, Purplish explores the many stories the state capitol has to tell. Plus, just in time for Halloween, a Colorado haunting... and a reimagining of Ichabod Crane. 

Lung cancer in nonsmoking individuals is increasing worldwide and currently accounts for 15% to 20% of lung cancer cases globally. Benjamin Solomon, PhD, of the Peter MacCallum Cancer Centre in Melbourne, Australia, discusses the epidemiology and treatment of lung cancer in nonsmoking patients with JAMA Deputy Editor Kristin Walter, MD, MS. Related Content: Lung Cancer in Nonsmoking Individuals ----------------------------------- JAMA Editors' Summary